TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

Benzinga Newsdesk www.benzinga.com Positive 86.5%

Neg 0% Neu 0% Pos 86.5%

TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $424 to $454.